Full inhibition of liver stage parasite development will lead to true causal prophylaxis. Failure to develop a drug with true causal prophylactic activity against malaria is mostly related to the ...

With malaria being one of the most significant causes of morbidity and mortality worldwide, prompt and effective treatment is essential to reduce the malaria burden. As there are several treatment ...

US-based pharmaceutical company 60 Degrees Pharmaceuticals has received approval from the investigational review board (IRB) for a Phase II trial of Arakoda (tafenoquine) for treating chronic ...

Cambodian scientist Yeang Chheang has spent six decades fighting malaria—even in the Khmer Rouge labor camp where his wife ...

Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company today announced ...

Degrees Pharmaceuticals (SXTP) announced that the United States Food and Drug Administration does not object to the company’s plan to import ...

An international research team led by Queen’s University Belfast is developing a long-acting preventative treatment for ...

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a ...

Zuhumnan said that the essence of the meeting was to analyse what was done in 2024 and seek ways to overcome challenges.

In the first year of the COVID-19 pandemic as researchers investigated potential treatments, infectious diseases physician ...

The main focus in this article is about cost–effectiveness of malaria patients in endemic areas treated therapeutically and using prophylaxis (IPT) when indicated. The cost–effectiveness with ...